Islet Transplantation in Type 1 Diabetes

Type 1 Diabetes Mellitus Clinical Trial

Official title:

Islet Transplantation in Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00434811
• Other study ID #: DAIT CIT-07
• Status: Completed
• Phase: Phase 3
• Start date: October 2006
• Est. completion date: May 2014

Study information

• Verified date: July 2019
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to determine the safety and effectiveness of islet transplantation, combined with immunosuppressive medications, for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes.

Description:

Type 1 diabetes is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump. Insulin therapy allows long-term survival in individuals with type 1 diabetes; however, it does not guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure. Some individuals with type 1 diabetes develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia. For such individuals, transplantation of pancreatic islets is a possible treatment option. Unfortunately, insulin independence among islet transplant recipients tends to decline over time. New strategies aimed at promoting engraftment of transplanted islets are needed to improve the clinical outcomes associated with this procedure. The purpose of this study is determine the safety and efficacy of islet transplantation, when combined with an immunosuppressive medication regimen, for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes. This study will also seek to improve the understanding of determinants of success and failure of islet transplants for type 1 diabetes.

Eligible participants will be randomly assigned to this study or a site-specific Phase 2 islet transplantation study. Participants in this study will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.

Transplantations will involve an inpatient hospital stay and infusion of islets into a branch of the portal vein. Participants who do not achieve or maintain insulin independence by Day 75 post-transplant will be considered for a second islet transplant. Participants who remain dependent on insulin for longer than 1 month after the second transplant and who show partial graft function will be considered for a third islet transplant. Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary. Participants who do not meet the criteria for a subsequent transplant and do not have a functioning graft will enter a reduced follow-up period.

There will be up to 19 study visits following each transplant. A physical exam, review of adverse events, and blood collection will occur at most visits. A chest x-ray, abdominal ultrasound, electrocardiogram, quality of life questionnaires, urine collection, and glomerular filtrating rate (GFR) testing will occur at some visits. Participants will also test their own blood glucose levels at least five times per day throughout the study. A 24-month follow-up period will take place after the participant's last transplant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 2014
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Mentally stable and able to comply with study procedures

• Clinical history compatible with type 1 diabetes with onset of disease at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28

• Absent stimulated C-peptide (less than 0.3 ng/ml) 60 and 90 minutes post-mixed-meal tolerance test

• Involvement of intensive diabetes management, defined as:

1. Self-monitoring of glucose values no less than a mean of three times each day averaged over each week

2. Administration of three or more insulin injections each day or insulin pump therapy

3. Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three clinical evaluations during the past 12 months prior to study enrollment

• At least one episode of severe hypoglycemia in the past 12 months, defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, compatible with hypoglycemia in which the individual required assistance of another subject was unable to treat him/herself person and which was associated with either a blood glucose level less than 54 mg/dl or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration in the 12 months prior to study enrollment

• Reduced awareness of hypoglycemia. More information about this criterion, including specific definition of hypoglycemia unawareness, is in the protocol.

Exclusion Criteria:

• Body mass index (BMI) greater than 30 kg/m2 or weight less than or equal to 50 kg

• Insulin requirement of more than 1.0 IU/kg/day or less than 15 U/day

• HbA1c greater than 10%

• Untreated proliferative diabetic retinopathy

• Systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg

• Measured glomerular filtration rate using iohexol of less than 80 ml/min/1.73mm2. More information about this criterion is in the protocol.

• Presence or history of macroalbuminuria (greater than 300 mg/g creatinine)

• Presence or history of panel-reactive anti-HLA antibody levels greater than background by flow cytometry. More information about this criterion is in the protocol.

• Pregnant, breastfeeding, or unwilling to use effective contraception throughout the study and 4 months after study completion

• Presence or history of active infection, including hepatitis B, hepatitis C, HIV, or tuberculosis.

• Negative for Epstein-Barr virus by IgG determination

• Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection in the past year

• History of malignancy except for completely resected squamous or basal cell carcinoma of the skin

• Known active alcohol or substance abuse

• Baseline Hgb below the lower limits of normal, lymphopenia, neutropenia, or thrombocytopenia

• History of Factor V deficiency

• Any coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or individuals with an INR greater than 1.5

• Severe coexisting cardiac disease, characterized by any one of the following conditions:

1. Heart attack within the last 6 months

2. Evidence of ischemia on functional heart exam within the year prior to study entry

3. Left ventricular ejection fraction less than 30%

• Persistent elevation of liver function tests at the time of study entry

• Symptomatic cholecystolithiasis

• Acute or chronic pancreatitis

• Symptomatic peptic ulcer disease

• Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with the ability to absorb oral medications

• Hyperlipidemia despite medical therapy, defined as fasting LDL cholesterol greater than 130 mg/dl (treated or untreated) and/or fasting triglycerides greater than 200 mg/dl

• Currently receiving treatment for a medical condition that requires chronic use of systemic steroids except for the use of 5 mg or less of prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only

• Treatment with any antidiabetic medication other than insulin within the past 4 weeks

• Use of any study medications within the past 4 weeks

• Received a live attenuated vaccine(s) within the past 2 months

• Any medical condition that, in the opinion of the investigator, might interfere with safe participation in the trial

• Treatment with any immunosuppressive regimen at the time of enrollment.

• A previous islet transplant.

• A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and the transplant occurred more than 6 months prior to enrollment.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Biological:
• Allogeneic Pancreatic Islet Cells
200 ml suspension of allogenic human purified islets
• Antithymocyte Globulin
Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.

Drug:
• Sirolimus
Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
• Tacrolimus
On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.

Biological:
• Etanercept
Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.

Procedure:
• Islet Transplantation
Transplantation of pancreatic islet cell

Biological:
• Basiliximab
Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta
United States	Emory University	Atlanta	Georgia
United States	Northwestern University	Chicago	Illinois
United States	University of Illinois, Chicago	Chicago	Illinois
United States	University of Miami	Miami	Florida
United States	University of Minnesota	Minneapolis	Minnesota
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Callifornia, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (5)

Harlan DM. Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor. Diabetes Care. 2016 Jul;39(7):1072-4. doi: 10.2337/dci16-0008. — View Citation

Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, Chaloner K, Czarniecki CW, Goldstein JS, Hunsicker LG, Kaufman DB, Korsgren O, Larsen CP, Luo X, Markmann JF, Naji A, Oberholzer J, Posselt AM, Rickels MR, Ricordi C, Robien MA, Senior — View Citation

Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, Fuller C, Chiou AJ, Barker CF, Luning Prak ET, Naji A. Improvement in ß-cell secretory capacity after human islet transplantation — View Citation

Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, Czarniecki CW, Barbaro B, Bridges ND, Cano J, Clarke WR, Eggerman TL, Hunsicker LG, Kaufman DB, Khan A, Lafontant DE, Linetsky E, Luo X, Markmann JF, Naji A, Korsgren O, Oberholzer J, Turgeon — View Citation

Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants with a HbA1c less than 7.0% AND free of severe hypoglycemic events	The proportion of participants with HbA1c =7.0% AND free of severe hypoglycemic events from Day 28 to Day 365 inclusive, following the first islet transplant, with the day of transplant designated Day 0.	From Day 28 to Day 365 (inclusive) following the first islet transplant, with the day of transplant designated Day 0
Secondary	Percent reduction in insulin requirements		75 days following the first and subsequent islet transplant
Secondary	HbA1c on Day 75 Status Post the First and Subsequent Islet Transplant	The target level for HbA1c for this study is 7.0%. This value is the level recommended by the American Diabetes Association and is considered to be the clinically relevant goal for subjects with Type 1 diabetes (T1D). A HbA1c level of 6.5% is the goal recommended by the American College of Endocrinology.	75 days following the first and subsequent islet transplant
Secondary	Mean amplitude of glycemic excursions (MAGE)	A MAGE >11.1 mmol/L (200 mg/dL) is indicative of marked glycemic lability.	75 days following the first and subsequent islet transplant
Secondary	Glycemic liability index (LI)		75 days following the first and subsequent islet transplant
Secondary	Ryan hypoglycemia severity score (HYPO)		75 days following the first and subsequent islet transplant
Secondary	Basal (fasting) and 90-minute glucose and C-peptide derived from mixed meal tolerance test (MMTT)		75 days following the first and subsequent islet transplant
Secondary	ß-score on Day 75 Status Post the First and Subsequent Islet Transplant	Beta-score: an assessment of beta-cell function after islet transplantation.	75 days following the first and subsequent islet transplant
Secondary	C-peptide:glucose creatinine ratio		75 days following the first and subsequent islet transplant
Secondary	Acute insulin response to glucose, insulin sensitivity, and disposition index derived from the insulin-modified frequently sampled intravenous glucose tolerance (FSIGT) test		75 days following the first and subsequent islet transplant
Secondary	Glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system (CGMS)		75 days following the first and subsequent islet transplant
Secondary	Assessment of Quality of Life Using the Short Form 36 Health Survey: Day 75 Status Post First and Final Islet Transplant	The Short-Form 36 Health Survey (SF-36®) is comprised of 36 items and 2 component scores, the Physical Component Score and the Mental Component Score. Each component is transformed into a 0-100 scale (higher numbers indicate greater quality of life) and normalized to have a mean of 50 and standard deviation of 10 for the 1998 general US population. SF-36 results unit of measure: Units on a Scale.	75 days following the first and subsequent islet transplant
Secondary	Incidence of worsening retinopathy		365 days following the first islet transplant
Secondary	Proportion of insulin-independent Participants on Day 365 Status Post the First and Final Islet Transplant		365 days following the first and final islet transplant
Secondary	Percent reduction in insulin requirements		365 days following the first and final islet transplant
Secondary	HbA1c on Day 365 Status Post the First and Final Islet Transplant	The target level for HbA1c for this study is 7.0%. This value is the level recommended by the American Diabetes Association and is considered to be the clinically relevant goal for subjects with Type 1 diabetes (T1D). A HbA1c level of 6.5% is the goal recommended by the American College of Endocrinology.	365 days following the first and final islet transplant
Secondary	MAGE	A MAGE >11.1 mmol/L (200 mg/dL) is indicative of marked glycemic lability.	365 days following the first and final islet transplant
Secondary	Glycemic liability index (LI): Day 365 Status Post First and Final Islet Transplant		365 days following the first and final islet transplant
Secondary	Clarke score	The Clarke survey provides a composite indices of hypoglycemia frequency, severity, and symptom recognition.	365 days following the first and final islet transplant
Secondary	HYPO score	The HYPO(glycemia) score provides a composite indices of hypoglycemia frequency, severity, and symptom recognition.	365 days following the first and final islet transplant
Secondary	Basal (fasting) and 90-minute glucose and C-peptide (MTT)		365 days following the first and final islet transplant
Secondary	ß-score on Day 365 Status Post First and Final Islet Transplant	Beta-score: an assessment of beta-cell function after islet transplantation.	365 days following the first and final islet transplant
Secondary	C-peptide: glucose creatinine ratio		365 days following the first and final islet transplant
Secondary	Assessment of Quality of Life Using the Short Form 36 Health Survey: Day 365 Status Post First and Final Islet Transplant	The Short-Form 36 Health Survey (SF-36®) is comprised of 36 items and 2 component scores, the Physical Component Score and the Mental Component Score. Each component is transformed into a 0-100 scale (higher numbers indicate greater quality of life) and normalized to have a mean of 50 and standard deviation of 10 for the 1998 general US population. SF-36 results unit of measure: Units on a Scale.	365 days following the first and final islet transplant
Secondary	Proportion of participants receiving a second islet transplant		365 days following the first and final islet transplant
Secondary	Proportion of participants receiving a third islet transplant		365 days following the first and final islet transplant
Secondary	Incidence and severity of adverse events related to the islet transplant procedure		75 days following each transplant and 365 days following the first and final islet transplant
Secondary	Incidence and severity of adverse events related to the immunosuppression therapy		75 days following each transplant and 365 days following the first and final islet transplant
Secondary	Incidence of a change in the immunosuppression drug regimen		75 days following each transplant and 365 days following the first and final islet transplant
Secondary	Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation		75 days following each transplant and 365 days following the first and final islet transplant
Secondary	Proportion of insulin-independent participants on Day 75 Status Post First and Subsequent Islet Transplant		75 days following first and subsequent islet transplant
Secondary	Acute insulin response to glucose insulin sensitivity, and disposition index derived from the FSIGT test	Frequently Sampled Intravenous Glucose Tolerance (FSIGT), a measure of insulin-independence, a clinically relevant measure of islet graft function.	365 days following the first and final islet transplant

External Links

•   Division of Allergy, Immunology, and Transplantation (DAIT)
•   National Institute of Allergy and Infectious Diseases (NIAID)
•   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository Data for this Study